The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Roche; Tarveda Therapeutics
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Orion (Inst); Pfizer (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst)
A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.
 
Susana N. Banerjee
Honoraria - Roche
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Carrick Therapeutics (Inst); Clovis Oncology; GenMab; Merck; Roche; Seagen; Tesaro
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Nucana
 
Alvaro Ingles Russo
No Relationships to Disclose
 
Andrea Biondo
No Relationships to Disclose
 
Ionut-Gabriel Funingana
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Martin Little
Travel, Accommodations, Expenses - BerGenBio; Immutep
 
Toby Prout
Employment - Institute of Cancer Research
 
Mona Parmar
Employment - Institute of Cancer Research
 
Bora Gurel
Employment - Institute of Cancer Research
 
Ruth Riisnaes
No Relationships to Disclose
 
Ben Jenkins
Employment - Institute of Cancer Research
 
Emma Hall
Employment - Institute of Cancer Research
Research Funding - Accuray (Inst); Alliance Pharma (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); Bayer (Inst); Kiowa Kirin (Inst); Merck Sharp & Dohme (Inst); Varian Medical Systems (Inst)
 
Ed Ainscow
Employment - Carrick Therapeutics
Stock and Other Ownership Interests - AstraZeneca; Carrick Therapeutics; Mirati Therapeutics; Novartis; Shire
Patents, Royalties, Other Intellectual Property - Carrick Therapeutics Ltd, Cancer Research Technology Ltd, Imperial Innovations Ltd: Patent WO2019057825A1
 
Stuart McIntosh
Employment - Carrick Therapeutics
Stock and Other Ownership Interests - Carrick Therapeutics
Travel, Accommodations, Expenses - Carrick Therapeutics
 
Nina Tunariu
Speakers' Bureau - Janssen Oncology
 
Anna Rachel Minchom
Honoraria - Bayer; Faron Pharmaceuticals; Novartis Pharmaceuticals UK Ltd.
Consulting or Advisory Role - Janssen Oncology
Travel, Accommodations, Expenses - Imugene; Loxo
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Genmab; Novartis
Research Funding - Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Natalie Cook
No Relationships to Disclose
 
Bristi Basu
Consulting or Advisory Role - Eisai (Inst); Genmab (Inst); Roche (Inst)
Speakers' Bureau - Eisai
Research Funding - Celgene (Inst); Genmab (Inst)
Travel, Accommodations, Expenses - Bayer
 
Udai Banerji
Employment - Institute of Cancer Research
Honoraria - Astellas Pharma; Lilly
Consulting or Advisory Role - Boehringer Ingelheim; Janssen; Novartis; Phoenix Solutions
Research Funding - AstraZeneca (Inst); BTG (Inst); Chugai Pharma (Inst); Onyx (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bayer; Sierra Oncology